Skip to content
naulon
Not checkedNot checked for notices yet.

Anaplastic lymphoma kinase-special immunity and immunotherapy

Ye Guo, Hanfei Guo, Yongfei Zhang and 1 more

Frontiers in Immunology · 2022

doi:10.3389/fimmu.2022.908894 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Alterations in the anaplastic lymphoma kinase (ALK) gene play a key role in the development of various human tumors, and targeted therapy has transformed the treatment paradigm for these oncogene-driven tumors. However, primary or acquired resistance remains a challenge. ALK gene variants (such as gene rearrangements and mutations) also play a key role in the tumor immune microenvironment. Immunotherapy targeting the ALK gene has potential clinical applications. Here, we review the results of recent studies on the immunological relevance of ALK-altered tumors, which provides important insights into the development of tumor immunotherapies targeting this large class of tumors.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.